Table 2.
Summary of Validation Results
| Concordance Index 5% CI)* | O/E Ratio (95% CI)† | Mean Squared Error (95% CI) | ||
|---|---|---|---|---|
| MMRpro + MSI testing‡ | 0.83 (0.78 to 0.87) | 0.94 (0.84 to 1.05) | 0.18 (0.15 to 0.22) | |
| MMRpro | 0.79 (0.74 to 0.84) | 0.97 (0.86 to 1.08) | 0.19 (0.16 to 0.23) | |
| Leiden | 0.77 (0.71 to 0.83) | 1.54 (1.35 to 1.80) | 0.24 (0.20 to 0.28) | |
| Difference between MMRpro + MSI and Leiden | 0.06 (−0.02 to 0.14) | Not applicable§ | 0.06 (0.005 to 0.11) | |
| Sensitivity | Specificity | |||
| Revised Bethesda Guidelines + MSI|| | 0.72 | 0.69 | ||
| Revised Bethesda Guidelines | 0.77 | 0.54 | ||
| Amsterdam Criteria|| | 0.75 | 0.62 | ||
Abbreviations: CI, confidence interval; MSI, microsatellite instability.
*
Concordance index is equal to the area under the receiver operating characteristic curve.
†
Ratio between the observed number of carriers and the total number of predicted carriers.
‡
Represents MMRpro prediction after taking into account the MSI test results, when available.
§
Computing the difference in this case is not an appropriate comparison, as each of the ratios should be compared directly with the reference value of 1.
||
Refers to applying the revised Bethesda Guidelines, testing the individuals who fulfill the guidelines for MSI, and referring those individuals testing positive for MSI to germline testing.